Amarantus BioScience Holdings (AMBS) fair value: what the stock is really worth
As of Oct 23, 2026: fair value (intrinsic value) of Amarantus BioScience Holdings stock $0.00, price $0.00, upside +0.0%, quality 29 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?Yes
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine.
Show moreShow less
The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis.
Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion.
It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery.
In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns.
Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013.
Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.
Stock analysis
Amarantus BioScience Holdings (AMBS) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the data coverage at low.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Amarantus BioScience Holdings reported revenue of $95.3K in FY2022 versus $0 in FY2016. Reported net income was −$4.8M in FY2022.
Key figures
Market cap $63.0K Micro · EPS (TTM) $−0.0100 · Return on assets (EBIT) −3.9% · Free cash flow −$4.5M · Net debt $19.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 67% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 0%, AMBS screens richer than that median.
Fair Value models
Bear$0.0001Fair Value $0.0001Bull$0.0001
Price $0.0001 · Upside +0.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−83.2%
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+61.6%
’07
’08
’09
’11
’19
’20
’22
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,305.6% (2007) → −281.1% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2022 is a loss year, no rate is defined from a loss
Compare Amarantus BioScience Holdings with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 593 stocks
Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside+0.0% · Above median
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−46.7% · Bottom 25%
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)33· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Amarantus BioScience Holdings (AMBS) overvalued or undervalued?
As of Oct 21, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% upside (fairly valued).
What is the fair value of AMBS?
Our model-based fair value for Amarantus BioScience Holdings is $0.0001 (as of Oct 21, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of AMBS?
Amarantus BioScience Holdings has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amarantus BioScience Holdings (AMBS)?
Our model-based price target is the fair value of $0.0001 (as of Oct 21, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Amarantus BioScience Holdings stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus a price of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of Amarantus BioScience Holdings (AMBS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amarantus BioScience Holdings it is $0.0001 per share (as of Oct 21, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Amarantus BioScience Holdings stock overvalued or undervalued in 2026?
As of Oct 21, 2026, AMBS trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AMBS?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Amarantus BioScience Holdings the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amarantus BioScience Holdings worth?
The market values Amarantus BioScience Holdings at about $63.0K (market capitalisation, as of Oct 21, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Amarantus BioScience Holdings (AMBS)?
Balance-sheet figures for Amarantus BioScience Holdings (as of Oct 21, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is AMBS from its 52-week high?
Amarantus BioScience Holdings trades at $0.0001, about 67% below its 52-week high of $0.0003 and at the low of $0.0001 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to Amarantus BioScience Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amarantus BioScience Holdings stock attractive at the current price?
The data as of Oct 21, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AMBS calculated?
We run Amarantus BioScience Holdings through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.5 % above its aggregate fair value. Amarantus BioScience Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amarantus BioScience Holdings (AMBS)?
The closing price on Oct 23, 2026 was $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amarantus BioScience Holdings right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Amarantus BioScience Holdings
How large is the market capitalisation of Amarantus BioScience Holdings (AMBS)?
The market capitalisation of Amarantus BioScience Holdings is $63.0K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Amarantus BioScience Holdings (AMBS)?
Earnings per share at Amarantus BioScience Holdings are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Amarantus BioScience Holdings (AMBS)?
On an EBIT basis the return on assets of Amarantus BioScience Holdings is −3.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Amarantus BioScience Holdings (AMBS) generate?
The free cash flow of Amarantus BioScience Holdings is −$4.5M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Amarantus BioScience Holdings (AMBS) carry?
The net debt of Amarantus BioScience Holdings is $19.1M (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Amarantus BioScience Holdings in the live analysis
One click puts Amarantus BioScience Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 21, 2026